International Clinical Trial: A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07813468) titled 'A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: HC Biopharma Inc.

Condition: Cetuximab Bioequivalence Healthy Volunteers Pharmacokinetics

Intervention: Drug: HC034S

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: September 5, 2026...